Let There Be Germicidal Light: This $500 Fixture Could Stop the Next Pandemic, from Complex Systems

Watch Episode Here

Listen to Episode Here

Show Notes

Every so often a technology shows up that is cheap, well understood, and almost entirely unused — and the interesting question stops being "does it work?" and becomes "why isn't it everywhere?" That's the shape of this conversation, a cross-post from Complex Systems, where Patrick McKenzie (patio11) sits down with Aerolamp CEO Misha Gurevich and Chief Scientist Vivian Belenky, a researcher at Columbia University, to talk about germicidal light.

The technology is far-UVC: ultraviolet light at roughly 222 nanometers. Belenky's explanation of why it's different from the UV you already know is the crux of the episode. Far-UVC is absorbed by the DNA and RNA of pathogens and by essentially all proteins — and that second fact is what makes it safe. Humans carry a roughly 20-micron layer of dead skin cells, the stratum corneum, that is packed with protein and absorbs almost the entire dose before it reaches living tissue. Longer germicidal wavelengths used in water treatment, 254 and 265 nanometers, don't have that protein absorption and are genuinely unpleasant to be exposed to. Eyes are the more complicated case, protected mechanically rather than chemically — by eyelids, lashes, brow ridge — but as Belenky puts it, the failure mode is "like looking into a bright light and not like looking into an infrared laser": you flinch, and flinching is protective.

The efficacy numbers are the part that should make you sit up. Belenky describes far-UVC as functionally equivalent to an extremely strong air purifier — not one or two extra air changes per hour, but the equivalent of 30 to 50. The room-scale version of that claim has been demonstrated in the literature; see Far-UVC (222 nm) efficiently inactivates an airborne pathogen in a room-sized chamber in Scientific Reports. The headline result in the episode is newer and less settled: a trial underway in South Africa, using guinea pigs exposed to hospital-ward air, showing roughly 90% suppression of tuberculosis transmission. Belenky is careful about it, and so are we — it's preliminary, and we could find no published paper or preprint behind the figure. What makes it striking is that tuberculosis is resistant to far-UVC, perhaps ten times more so than a typical respiratory virus.

That resistance sets up the most counterintuitive argument in the conversation. Belenky is candid that she is less confident far-UVC will prevent the average common cold — colds mostly spread through close, extended contact — and more confident it could blunt a future respiratory pandemic. The reason is that contagion cuts both ways: the more transmissible a pathogen is, the more of its spread happens at range through shared air, and the more surface area there is for an intervention to bite. The historical precedent is measles, with a reproduction number around 20, which older 254-nanometer germicidal UV was used to control. COVID-19 at its worst was somewhere around 1-point-something.

So why isn't this everywhere? Both guests land on the same answer, and it isn't cost or science. McKenzie offers his own framing — that anything which fits in a shipping container from, without loss of generality, China craters in price over time, which puts far-UVC on a very different cost curve from most medical interventions. Gurevich's numbers bear that out: roughly 250 square feet of coverage per lamp, two to three lamps for a standard classroom, about $500 a lamp, and a rule of thumb that professional installation costs about what the lamps cost. Crucially, because 222 nm is innately safe, you don't need a specialist — as Gurevich notes, older wavelengths had to be installed by experts because a botched install caused eye damage within minutes, whereas "you can't really mess up a 222 installation that badly." Any electrician can hang it.

The real bottleneck is awareness. "Most people have never even heard of UV for disinfection," Gurevich says, "but even among people who have heard of UV for disinfection, almost no one has heard of 222." Belenky's version is sharper: far-UVC is currently in the social category of things only weird people do, like wearing a respirator everywhere, when what it needs to become is hand-sanitizer stations — unremarkable infrastructure nobody thinks about. Asked where a hypothetical first million dollars should go, the two split: Gurevich says awareness, Belenky says trial deployments, on the theory that visible normal-looking installations do the persuading better than a celebrity would. (Asked to pick a celebrity anyway, Gurevich passes on Taylor Swift in favor of Paris Hilton — on the logic that if high-end hotel brands get associated with clean air, that's worth a great deal.)

Two obstacles get real airtime. The first is the heckler's veto: formal studies are extraordinarily vulnerable to a single objector, since one uncomfortable participant can stop an IRB from approving an installation. Belenky's workaround is elegant — ordinary commercial deployment is far less vulnerable, and nothing stops you from studying a system after a building owner has installed it because they wanted it. The second is the hygiene hypothesis objection, which Belenky rejects firmly: modern understanding holds that immune training comes from environmental and commensal microorganisms, not from clinical illness. Catching RSV is neutral-to-negative for future immunity; measles actively wrecks immunological memory. "It is purely just bad to catch a virus and get sick." McKenzie's rejoinder, that we could always intentionally infect ourselves if we ever dropped below some optimal illness level, draws the best line of the episode from Belenky: "I think this is actually called vaccines."

On whether you should buy one, the guests disagree productively. Gurevich thinks most private homes don't pencil out at $500 — not enough transmission in a household of four. Belenky pushes back from experience, having had a baby two months before recording and run lamps in her living room when hosting company postpartum. Her argument is that illness is expensive enough, and infants vulnerable enough, that the math changes fast at the margins. Where they agree: the concentrated social returns are in schools, transport hubs, long-term care, and other places where strangers share air.

Nathan's own view, from the intro: he and his wife installed an Aerolamp over his son's bed during cancer treatment last winter, and with his son headed back to school he's buying lights for his sons' classrooms.

Resources

• The original episode, with full transcript — on the Complex Systems site
• Aerolamp — FAQ, dev kit
• Complex Systems with Patrick McKenzie
• ASHRAE Standard 241, Control of Infectious Aerosols
• Far-UVC (222 nm) efficiently inactivates an airborne pathogen in a room-sized chamber — Scientific Reports, 2022
• Far-UVC for clean indoor air — a talk by Vivian Belenky
• SecureBio — pandemic-prevention organization referenced in Nathan's intro; Jeff Kaufman

Note: the South African tuberculosis trial and its ~90% transmission-suppression figure are described in the episode as preliminary and unpublished. We could not locate a paper or preprint; treat it as reported by the guests rather than as a published result.

Sponsors:

Deepgram Flux TTS:

Deepgram Flux TTS brings lifelike AI voices with real personalities that handle interruptions, pauses, and natural conversation. Try all the voices free through September 12 at https://deepgram.com/keep-talking

Granola:

Granola is an AI-powered notepad that securely transcribes meetings and turns rough notes into clean, structured action items. Try it free at https://granola.ai/tcr

Claude:

Claude by Anthropic is an AI collaborator that understands your workflow and helps you tackle research, writing, coding, and organization with deep context. Get started with Claude and explore Claude Pro at https://claude.ai/tcr

CHAPTERS:

(00:00) About the Episode

(03:19) Far-UVC science and safety

(12:41) Deployment and economics (Part 1)

(18:04) Sponsors: Deepgram Flux TTS | Granola

(20:04) Deployment and economics (Part 2)

(27:11) Evidence and pandemics (Part 1)

(32:43) Sponsor: Claude

(34:13) Evidence and pandemics (Part 2)

(38:14) Built environment strategy

(47:27) Scaling and home use

(56:06) Uncertainty and immunity

(01:05:38) Risk and awareness

(01:20:45) Episode Outro

(01:24:26) Outro

PRODUCED BY:

https://aipodcast.ing

SOCIAL LINKS:

Website: https://www.cognitiverevolution.ai

Twitter (Podcast): https://x.com/cogrev_podcast

Twitter (Nathan): https://x.com/labenz

LinkedIn: https://linkedin.com/in/nathanlabenz/

Youtube: https://youtube.com/@CognitiveRevolutionPodcast

Apple: https://podcasts.apple.com/de/podcast/the-cognitive-revolution-ai-builders-researchers-and/id1669813431

Spotify: https://open.spotify.com/show/6yHyok3M3BjqzR0VB5MSyk

Transcript

Read the transcript on the Complex Systems podcast website.